StoneX Group’s Accelerate Diagnostics AXDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-1,194
Closed -$9.67K 661
2023
Q2
$9.67K Sell
1,194
-42
-3% -$315 ﹤0.01% 576
2023
Q1
$8.65K Sell
1,236
-85
-6% -$511 ﹤0.01% 612
2022
Q4
$9.32K Sell
1,321
-140
-10% -$1.53K ﹤0.01% 556
2022
Q3
$22.2K Buy
1,461
+250
+21% +$4.14K ﹤0.01% 486
2022
Q2
$12K Buy
+1,211
New +$10.7K ﹤0.01% 665
2021
Q4
Sell
-1,074
Closed -$63K 578
2021
Q3
$63K Sell
1,074
-100
-9% -$6.52K 0.01% 460
2021
Q2
$95K Sell
1,174
-40
-3% -$3.18K 0.01% 462
2021
Q1
$101K Hold
1,214
0.02% 405
2020
Q4
$92K Hold
1,214
0.02% 360
2020
Q3
$129K Sell
1,214
-460
-27% -$63.9K 0.04% 320
2020
Q2
$254K Sell
1,674
-80
-5% -$7.89K 0.1% 235
2020
Q1
$144K Buy
1,754
+400
+30% +$56.3K 0.08% 236
2019
Q4
$229K Hold
1,354
0.09% 261
2019
Q3
$251K Buy
1,354
+100
+8% +$19.3K 0.16% 196
2019
Q2
$287K Hold
1,254
0.18% 171
2019
Q1
$264K Hold
1,254
0.2% 182
2018
Q4
$144K Hold
1,254
0.14% 195
2018
Q3
$288K Buy
1,254
+150
+14% +$33.2K 0.21% 170
2018
Q2
$246K Sell
1,104
-75
-6% -$16.8K 0.21% 189
2018
Q1
$269K Hold
1,179
0.26% 153
2017
Q4
$309K Hold
1,179
0.32% 126
2017
Q3
$265K Hold
1,179
0.33% 124
2017
Q2
$322K Buy
+1,179
New +$320K 0.1% 260

Other funds holding AXDX

StoneX Group's AXDX Position: Q3 2023 in Review

StoneX Group sold out of Accelerate Diagnostics (AXDX) in Q3 2023, closing a stake of 1,194 shares — an estimated $9.67K sold.

StoneX Group first reported a position in AXDX in Q2 2017 and held it in 23 quarters. The position peaked at $322K in Q2 2017. 38 funds tracked by Wall St. Rank hold AXDX as of Q3 2023.

  • StoneX Group reported no remaining Accelerate Diagnostics position as of Q3 2023 after selling out during the quarter.
  • StoneX Group sold 1,194 Accelerate Diagnostics shares in Q3 2023, an estimated $9.67K.
  • StoneX Group first reported a position in Accelerate Diagnostics in Q2 2017 and held it in 23 quarters.
  • StoneX Group's Accelerate Diagnostics position peaked at $322K in Q2 2017.
  • 38 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2023.

Based on StoneX Group's 13F filing for Q3 2023, filed 15 Nov 2023.